Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer

Trial Details

NCT ID

NCT04136782

Phase

PHASE4

Sponsor

Shengjing Hospital

Status

RECRUITING

Cancer Type

Triple Negative (TNBC) Breast Cancer

Interventions

• Albumin-bound paclitaxel combined with carboplatin
• Epirubicin combined with docetaxel

Locations (sample)

• Harbin, Heilongjiang, China|45.75,126.65
• Changchun, Jilin, China|43.88,125.32278
• Dalian, Liaoning, China|38.91222,121.60222
• Panjin, Liaoning, China|41.121,122.0739
• Shenyang, Liaoning, China|41.79222,123.43278

Key Eligibility Criteria

• patients developing breast cancer as confirmed by X-ray examination, cancer tissue negative for estrogen receptor, progesterone receptor and HER2, …
• estimated survival \> 3 months;
• presence of clinically measurable lesions;
• Karnofsky functional status score ≥ 70;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.